ArticleScientific reports2025
Bidirectional reinforcement learning neural network for constrained molecular design.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present BiRLNN, a bidirectional molecular design framework that combines recurrent neural networks with reinforcement learning to optimize drug-like properties of generated compounds. We examined the use of Self-Referencing Embedded Strings representations, which ensures 100% syntactic validity of generated molecules. By generating molecular sequences in both forward and backward directions, we enabled more balanced exploration of chemical space while maintaining constraint requirements during molecular design. To guide generation towards desirable pharmacological targets, we implement a multi-objective reward function based on quantitative estimate of drug-likeness and synthetic accessibility, and apply policy gradient-based reinforcement learning for fine-tuning. We demonstrate that our bidirectional model covers the full constrained chemical space compared to unidirectional ones using pharmaceutically relevant fragments, allowing it to explore regions containing molecules unreachable by the latter. Moreover, the reinforcement learning process successfully steers the constrained generation process toward desirable compound classes with improved reward metrics. Our results demonstrate that BiRLNN offers a robust and flexible strategy for navigating chemical space in multi-objective drug design tasks.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.